Biointron Insights: Antibody Industry Trends (Q1 2026 Insights, Trends & Analysis)

Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.

1. Libevitug (华优诺)

2. Retlirafusp Alfa (艾泽利)

3. Amdokitug (益赛拓)

Q1 2026 saw many acquisitions, collaborations, and licensing agreements for bispecific and trispecific antibody drugs. Significant investment has been directed toward startups targeting a diverse range of therapeutic areas, such as central nervous system (CNS) disorders and inflammatory diseases.

Gain exclusive insights into current trends such as:

• 3 novel antibody drugs approved for the first time in Q1 2026

• Top 20 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8.5B

• Trends in early developability for antibody discovery

• Current research into multiple myeloma treatments

• A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q2 2026

Register now for a free download of the report!